Share
Hepatitis C Drug Market: By Product (NS5A Inhibitor (Protease Inhibitors), Fixed-dose Combination), By Disease Type (Acute Hepatitis C, Chronic Hepatitis C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And Region - Global Analysis of Market Size, Share & Trends For 2021-2022 And Forecasts To 2032
[170+ Pages Research Report] Hepatitis C Drug Market to surpass USD 8.87 billion by 2032 from USD 6.73 billion in 2021 at a CAGR of 2.5% throughout the forecast period 2022-32
Hepatitis C is a viral infection that leads to damage of the liver like severe inflammation and spreads through contaminated blood. Hepatitis C advanced stages lead to damage of liver, leading to major health risks. The Research and Development of drugs related to treatment of this disease increased due to the severity caused by hepatitis C. Due to the wide spread presence of hepatitis C, many new drugs are being identified and launched into the market. This disease requires oral injections dosage every weekly, and it leads to many side effects that might cause a permanent damage. Rise in clinical trials success has aided the hepatitis C market growth due to better drug clearances. Even the increase in regulatory approvals number will grow the hepatitis C market in the future.
The global hepatitis C drug market size was valued at 6.73 billion USD in 2021 and is projected to attain at 8.87 billion USD by 2032, exhibiting a CAGR of 2.5% during the forecast period. Hepatitis C market is at present at a unique position where the entry of new products into the market like the fixed-dose combination products which resulted in increased revenues generation by competing companies. The high prices of hepatitis C medicals is assigned due to the high costs along with the Research & Development procedures and the costs to bring drugs into the market.
Figure - Market Analysis of Hepatitis C Drug Market
Hepatitis C drug market globally is classified based on the product into Fixed-dose Combination, NS5A Inhibitor (Protease Inhibitors) and Others. The Fixed-dose Combination segment is expected to have a major share of the Hepatitis C therapeutics market due to the extreme therapy which is efficient for the treatment of Hepatitis. This segment is estimated to grow at a highest CAGR due to the features which are favourable like effectiveness in all the genotypes & due to the product launches held recently. There are several major drugs present in this segment, which result in acquiring new drug therapies.
Hepatitis C drug market is classified based on the disease type into acute Hepatitis C and Chronic Hepatitis C. In the disease type, the chronic Hepatitis C segment is expected to rise at a faster pace. This is due to all the acute Hepatitis C conditions converts into chronic form. Chronic Hepatitis C causes a long-term illness which needed a prolonged treatment or even for life time which is a factor contributing to the increase in the Hepatitis C drug market.
Figure - Market Analysis of Hepatitis C Drug Market
Invention of New Efficient Drugs
Globally, patient pool suffering from hepatitis C is large. There is a variation in trend being observed in patients due to increased effectiveness of drugs in treatment of Hepatitis C. The drugs used in the hepatitis C treatment are efficient and are superior resulting in reduced patient population indicating their superior extended activity. Novel advancements in technology to help in reducing the treatment cost will rise the demand for Hepatitis C drug market due to increase in Research & Development
Rise in Awareness and Support by Government
One of the forms of the hepatitis C, called the acute hepatitis C which will aid in the technical advancements and development of new treatment drugs. Certain initiatives by the government are made to improve the healthcare sector, to reduce the occurrence of Hepatitis C and the increased awareness about the disease burden is also a factor aiding the market growth.
High Production Cost
The raw materials required for the manufacture of Hepatitis C drugs are high which might result in high production cost, high cost of finished product and in turn the investment required is high. Every step involved in the production like utilisation of raw materials and isolation involve a complex procedure which increases the overall cost of pharmaceuticals. Even the acute Hepatitis C at an early stage may not require the prescribing of therapeutic drugs. This is expected to restrain the market share of Hepatitis C drugs.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Hepatitis C Drug market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. North America is dominating the Hepatitis C drug market and is expected to rise in the market even during forecast period. Due the existence of large patient pool in these countries and concentration of patients suffering from hepatitis C in the area, result in high market growth of Hepatitis C drug. The prescribing of hepatitis C therapeutics is at a higher rate among healthcare providers and several patients are getting treated utilising these drugs. So, the launch of new medicines along with the strong Research and Development is helping the hepatitis C drug market to grow.
Get More Information - Download Free Sample
The lockdowns imposed by several countries to prevent the spread of Covid-19 resulted in the global operations and supply chain delay causing negative consequences on the Hepatitis C Drug market. The global sales declined as the professionals involved in this healthcare diverted their attention on to coronavirus-infected patients. The key players in the market have suspended the production of Hepatitis C drugs temporarily for treating the patients affected with the Covid 19.
North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
Global Hepatitis C Drug Market Segments:
By Product
REPORT ATTRIBUTE |
DETAILS |
|
Market size value in 2021 |
USD 6.73 billion |
|
Revenue forecast in 2032 |
USD 8.87 billion |
|
Growth Rate |
CAGR of 2.5% from 2022 to 2032 |
|
Base year for estimation |
2021 |
|
Quantitative units |
Revenue in USD million and CAGR from 2022 to 2032 |
|
Report coverage |
Competitive landscape, Revenue forecast, Company ranking, growth factors, and trends |
|
Segments covered |
Product, Disease Type, Distribution Channel and Region |
|
Regional scope |
Europe, North America, Latin America, Asia Pacific, Middle East & Africa (MEA) |
|
Key companies profiled |
AbbVie Inc, Gilead Sciences Inc., Janssen Pharmaceuticals Inc., Kenilworth, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., F. Hoffmann-La Roche Ltd, Basel GlaxoSmithKline, Zydus Cadilla, LAURUS Labs, Hetero Healthcare Limited, Cipla Inc., Vertex Pharmaceuticals and Other Prominent Players |
Hepatitis C Drug market size was estimated at USD 6.73 billion in 2021 and is estimated to reach USD 8.87 billion by 2032
Hepatitis C is a viral infection that leads to damage of the liver like severe inflammation and spreads through contaminated blood. Hepatitis C advanced stages lead to damage of liver, leading to major health risks
Fixed-dose Combination segment and Chronic Hepatitis C market accounted for the largest Hepatitis C Drug market share.
Key players: AbbVie Inc, Gilead Sciences Inc., Janssen Pharmaceuticals Inc., Kenilworth, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., F. Hoffmann-La Roche Ltd, Basel GlaxoSmithKline, Vertex Pharmaceuticals, Zydus Cadilla, LAURUS Labs, Hetero Healthcare Limited, Cipla Inc. and Other Prominent Players are the key players in the Hepatitis C Drug.
Invention of New Efficient Drug and Rise in Awareness and Support by Government are the factors driving the Hepatitis C Drug market.
Select License Type
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT
Working with Fatpos Global, allowed us to take advantage of their knowledge and easy approach, allowing us to collect important data utilizing a variety of techniques. The results were clearly presented and explained, and FG responded to our questions with speed and expertise.
|
Swiss-based global building materials manufacturer |
The analyses and presentations Fatpos Global have produced for us have been of a very high caliber and have allowed us to proactively improve our customer relationship management. They have also done so while maintaining complete anonymity. Without any doubt, we suggest Fatpos Global to you.
|
|
Tech-powered construction company |
We appreciate the team’s punctuality, flexibility in terms of report modification, post report purchase support and pleasant reaction all around. Overall, my experience with this company was nothing but positive, and I couldn't be more grateful for their excellent service. Thank you for all that you do!
|
|
American global management consulting firm |
We are able to concentrate on the topics and implications that are most important to our clients thanks to the adaptability and responsiveness of the team at Fatpos Global. We would highly recommend this company to anyone in need of their services, and I will certainly be using them again in the future.
|
|
Headquartered in Zug, Switzerland, leading supplier of medical and surgical instrument |
To better study our client demographics, develop the ideal product-price architecture, and enhance our target marketing initiatives, we hired Fatpos Global. Every component of the project was completed, and we are very happy with the useful insights and actionable results.
|
|
Kosovan company, A leading organic fertilizers producer |
Thank you for your team's generous assistance, The final report was delivered to me, and I find it to be really helpful. Also, you may be sure that I will get in touch with you if I ever require fresh materials for market research. Gratitude once more.
|
|
German specialty chemicals company based in Cologne, Germany |
